Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

The sudden departure of Novo Nordisk chief executive Lars Fruergaard Jørgensen comes not amid scandal or strategic calamity, ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market ... as its obesity injection Wegovy loses ground to Eli Lilly's rival treatment ...